Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||SBT6050 + Trastuzumab deruxtecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SBT6050||SBT-6050|SBT 6050|ImmunoTAC SBT6050|HER2-directed TLR8 Agonist SBT6050||HER2 (ERBB2) Antibody 57 TLR8 Agonist 7||SBT6050 comprises a TLR8 (CD288) agonist linked to an Erbb2 (Her2) monoclonal antibody, which may lead to activation of TLR8 expressing myeloid cells in the context of Erbb2 (Her2)-expressing tumors, potentially resulting in increased anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 4537).|
|Trastuzumab deruxtecan||Enhertu||DS-8201|DS8201a|T-DXd|DS-8201fam-trastuzumab deruxtecan-nxki||HER2 (ERBB2) Antibody 57||Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate comprising an anti-ERBB2 (HER2) antibody linked to a derivative of the topoisomerase inhibitor DX-8951, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of tumors, including tumors with low ERBB2 (HER2) expression (PMID: 27026201). Enhertu (fam-trastuzumab deruxtecan-nxki) is FDA approved for use in patients with ERBB2 (HER2)-positive breast cancer who have received two or more anti-HER2 therapies previously, and in patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05091528||Phase Ib/II||SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib||A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers||Active, not recruiting||USA||0|